Abstract
Of the 24 million people with schizophrenia worldwide, fewer than 50% receive appropriate care.¹ Even patients with access to the best available treatments suffer from significant functional and social deficits.² This article is based on a teleconference that discussed issues related to the development of new treatments for schizophrenia.